Peptide Therapy · ARA-290 · Serving South Metro Denver

Individual experiences can vary, and there is no established timeframe or guarantee of results with ARA-290. Your provider can discuss expectations and how progress may be monitored.

No. ARA-290 is investigational and is not FDA-approved for the treatment or prevention of any medical condition. At Oasis, peptide care is provided within a medically supervised program that includes provider evaluation, individualized guidance, and ongoing monitoring—rather than being sold as a self-directed “research use only” product online.

No. Although ARA-290 is derived from part of the EPO molecule, it was designed to activate tissue-protective pathways without the red blood cell–stimulating effects associated with EPO.

Whether ARA-290 is appropriate alongside another peptide or therapy depends on the individual. At Oasis, combinations should be considered only after provider review to evaluate goals, medications, medical history, and potential risks.

We kindly ask for at least 24 hours’ notice to cancel or reschedule your appointment. Cancellations within 24 hours will incur a 50% fee. If we arrive and are unable to reach you or access the appointment location after a brief grace period, the visit will be considered a no-show and may be charged up to the full service amount. Same-day bookings require a minimum of 4 hours’ notice for any changes. As each appointment is reserved exclusively for you — including provider time and travel — we appreciate your understanding.

A few. We don’t treat patients during active pregnancy or while breastfeeding (with most formulations). Patients with kidney disease, congestive heart failure, liver disease, history of seizures, or certain blood disorders need a quick conversation with us before booking. If you have a pacemaker or any cardiac device, please mention it when you call. Your pre-visit health screening will catch most of this — we’ll never proceed if it’s not safe.

No. Not everyone will be an appropriate candidate, particularly because clinical evidence remains limited. A medical evaluation is important before considering ARA-290.